GBS - GBS announces a collaboration to develop saliva-based diagnostic tests

GBS Inc. ([[GBS]] +11.7%) has surged today after announcing a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to speed up the development of saliva-based diagnostic tests.The research partnership is expected to back the commercialization of two non-invasive, rapid point of care diagnostic tests currently undergoing development at GBS: the SARS-CoV-2 Antibody Biosensor and, for people living with diabetes, the Saliva Glucose Biosensor.Yesterday, another collaboration between GBS with Wyss Institute at Harvard University was announced. It seeks to 'validate and de-risk' a COVID-19 diagnostic.

For further details see:

GBS announces a collaboration to develop saliva-based diagnostic tests